Zeldox Bold Interaction Warning, Not Black Box, Needed For QTc - Committee

Labeling for Pfizer's Zeldox (ziprasidone) should clearly warn against combination use with other drugs that may prolong the QTc interval, but a black box may not be necessary, FDA's Psychopharmacological Drugs Advisory Committee suggested July 19.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet